NASDAQ:QUREUniqure Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Uniqure NV Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $45.55 -1.41 (-3.00 %) (As of 04/3/2020 04:00 PM ET) Add Compare Share Today's Range$44.90Now: $45.55▼$47.2850-Day Range$40.01MA: $51.29▼$64.8852-Week Range$36.20Now: $45.55▼$82.49Volume133,197 shsAverage Volume414,293 shsMarket Capitalization$2.02 billionP/E RatioN/ADividend YieldN/ABeta1.11 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure. In addition, the company engages in developing AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment hemophilia A; AMT-190, a differentiated gene therapy for the treatment of Fabry disease; and AMT-150, a gene therapy for SCA3, a central nervous system disorder. The company has collaboration and license agreements with Bristol Myers-Squibb; 4D Molecular Therapeutics, LLC; and Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingUniqure has received a consensus rating of Buy. The company's average rating score is 2.92, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $86.00, Uniqure has a potential upside of 88.8% from its current price of $45.55.Amount of Analyst CoverageUniqure has only been the subject of 3 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesUniqure has received 570 “outperform” votes. (Add your “outperform” vote.)Underperform VotesUniqure has received 413 “underperform” votes. (Add your “underperform” vote.)Community SentimentUniqure has received 57.99% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Uniqure and other stocks. Vote “Outperform” if you believe QURE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe QURE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldUniqure does not currently pay a dividend.Dividend GrowthUniqure does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Uniqure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,946,134.00 in company stock.Percentage Held by InsidersOnly 2.91% of the stock of Uniqure is held by insiders.Percentage Held by Institutions78.17% of the stock of Uniqure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Uniqure are expected to decrease by -11.61% in the coming year, from ($3.53) to ($3.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Uniqure is -14.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Uniqure is -14.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUniqure has a P/B Ratio of 6.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.47 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:QURE Previous Symbol CUSIPN/A CIK1590560 Webhttp://www.uniqure.com/ Phone31-20-240-6000Debt Debt-to-Equity Ratio0.11 Current Ratio12.15 Quick Ratio12.15Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$7.28 million Price / Sales276.93 Cash FlowN/A Price / Cash FlowN/A Book Value$7.41 per share Price / Book6.15Profitability EPS (Most Recent Fiscal Year)($3.11) Net Income$-124,200,000.00 Net Margins-1,705.82% Return on Equity-51.62% Return on Assets-34.44%Miscellaneous Employees212 Outstanding Shares44,260,000Market Cap$2.02 billion Next Earnings Date5/4/2020 (Estimated) OptionableOptionable Receive QURE News and Ratings via Email Sign-up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:QURE Rates by TradingView Uniqure (NASDAQ:QURE) Frequently Asked Questions How has Uniqure's stock been impacted by COVID-19 (Coronavirus)? Uniqure's stock was trading at $47.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, QURE shares have decreased by 4.2% and is now trading at $45.55. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Uniqure? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Uniqure in the last year. There are currently 1 hold rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Uniqure. When is Uniqure's next earnings date? Uniqure is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Uniqure. How were Uniqure's earnings last quarter? Uniqure NV (NASDAQ:QURE) posted its earnings results on Monday, March, 2nd. The biotechnology company reported ($0.97) earnings per share for the quarter, missing analysts' consensus estimates of ($0.78) by $0.19. The biotechnology company had revenue of $2.63 million for the quarter, compared to analyst estimates of $1.76 million. Uniqure had a negative return on equity of 51.62% and a negative net margin of 1,705.82%. View Uniqure's earnings history. What price target have analysts set for QURE? 13 equities research analysts have issued 12-month price objectives for Uniqure's shares. Their forecasts range from $73.00 to $105.00. On average, they expect Uniqure's stock price to reach $86.00 in the next year. This suggests a possible upside of 88.8% from the stock's current price. View analysts' price targets for Uniqure. What are Wall Street analysts saying about Uniqure stock? Here are some recent quotes from research analysts about Uniqure stock: 1. According to Zacks Investment Research, "UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. " (1/23/2020) 2. HC Wainwright analysts commented, "Enrollment completion in the HOPE-B registration study positions 12+month lead. We now anticipate data during 4Q20, with likely commercial launch during 4Q21, ahead of our prior 2H-2022 expectations. We continue to believe, AMT-061 remains the one-and-done therapy of choice based on: (1) the ability to successfully treat subjects with NAB’s to the peer construct; (2) low-levels of NABs to AAV5, which is a significant commercial differentiator, compelling centers to choose a therapy that could benefit the majority of patients i.e., >90% in case of AMT-061, over one with at least 40% exclusion criteria; and (3) no prophylactic steroids." (9/3/2019) 3. Chardan Capital analysts commented, "We continue our bullish QURE thesis (and affirm our $175 price target) ahead of what we see as among the most compelling 2020 catalysts in biotech:." (9/3/2019) Has Uniqure been receiving favorable news coverage? Press coverage about QURE stock has been trending very negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Uniqure earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutUniqure. Are investors shorting Uniqure? Uniqure saw a drop in short interest in the month of March. As of March 13th, there was short interest totaling 4,136,000 shares, a drop of 9.5% from the February 27th total of 4,570,000 shares. Based on an average daily volume of 427,500 shares, the short-interest ratio is currently 9.7 days. Currently, 19.7% of the shares of the company are short sold. View Uniqure's Current Options Chain. Who are some of Uniqure's key competitors? Some companies that are related to Uniqure include Elanco Animal Health (ELAN), Sarepta Therapeutics (SRPT), Catalent (CTLT), Mylan (MYL), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Horizon Therapeutics (HZNP), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Forty Seven (FTSV), Reata Pharmaceuticals (RETA) and United Therapeutics (UTHR). What other stocks do shareholders of Uniqure own? Based on aggregate information from My MarketBeat watchlists, some companies that other Uniqure investors own include Empire Resorts (NYNY), Micron Technology (MU), Alibaba Group (BABA), Exelixis (EXEL), NVIDIA (NVDA), Gilead Sciences (GILD), Crispr Therapeutics (CRSP), GW Pharmaceuticals PLC- (GWPH), Roku (ROKU) and AbbVie (ABBV). Who are Uniqure's key executives? Uniqure's management team includes the following people: Mr. Matthew Craig Kapusta, CEO, Interim CFO & Exec. Director (Age 47)Dr. Sander van Deventer M.D., Ph.D., Co-founder, Chief Scientific Officer & GM of Amsterdam (Age 65)Mr. Jonathan Garen, Chief Bus. Officer (Age 53)Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-GermanyDr. Scott T. McMillan, Chief Operations Officer (Age 60) What is Uniqure's stock symbol? Uniqure trades on the NASDAQ under the ticker symbol "QURE." How do I buy shares of Uniqure? Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Uniqure's stock price today? One share of QURE stock can currently be purchased for approximately $45.55. How big of a company is Uniqure? Uniqure has a market capitalization of $2.02 billion and generates $7.28 million in revenue each year. The biotechnology company earns $-124,200,000.00 in net income (profit) each year or ($3.11) on an earnings per share basis. Uniqure employs 212 workers across the globe. View additional information about Uniqure. What is Uniqure's official website? The official website for Uniqure is http://www.uniqure.com/. How can I contact Uniqure? Uniqure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at 31-20-240-6000 or via email at [email protected] This page was last updated on 4/4/2020 by MarketBeat.com StaffFeatured Article: Growth and Income Funds
